Antimicrobial resistant superbugs could kill millions, cost $2 trillion yearly by 2050: Report
Antimicrobial-resistant superbugs could lead to substantial global mortality and economic losses of approximately $2tn annually by 2050, according to a study, quoted by the Guardian.
Analysis from a UK government-sponsored research reveals that rising antimicrobial resistance (AMR) could result in yearly global GDP losses of $1.7 trillion over the next 25 years without decisive intervention.
The Center for Global Development's research indicates severe economic impact on the US, UK and EU economies. Recent reductions in aid funding appear counterproductive, particularly as the UK government has eliminated Fleming fund support for AMR prevention in developing nations.
Similarly, the US has confirmed $9 billion in foreign aid reductions, with European nations following suit.
Anthony McDonnell, who led the research at the Center for Global Development, explained that initial projections were based on historical resistance trends. He noted that significant aid reductions by the US (80%), UK (from 0.5% to 0.3% of GNI), France, and Germany could accelerate resistance rates to worst-case scenarios.
He emphasised that no country, regardless of their AMR control success, should be complacent. Without protecting AMR programmes from funding cuts, global resistance rates could escalate to match severely affected nations, resulting in increased mortality worldwide and substantial economic consequences.
The study, covering 122 countries, projects annual GDP losses by 2050 could reach $722 billion in China, $295.7 billion in the US, $187 billion in the EU, $65.7 billion in Japan, and $58.6 billion in the UK under pessimistic scenarios.
The Institute for Health Metrics and Evaluation forecasts a 60% increase in AMR-related deaths by 2050, with annual mortality reaching 1.34 million in the US and 184,000 in the UK. Drug-resistant infections are expected to rise significantly.
Antibiotic-resistant infections double treatment costs due to increased hospitalisations, extended stays, expensive alternative treatments, and complex care requirements.
The research estimates global AMR treatment costs could rise by $176bn annually, with UK costs increasing from $900m to $3.7bn and US costs from $15.5bn to $57bn.
The study indicates workforce reductions of 0.8% in the UK, 0.6% in the EU, and 0.4% in the US due to resistant infections.
However, increased investment in addressing superbugs could boost annual economic growth by $156.2bn in the US and $12bn in the UK by 2050.
Dr Mohsen Naghavi from IHME warned that without immediate action, current medicines might become ineffective, potentially making simple infections lethal, according to The Guardian.
This requires governmental policy changes, new drug development, and public education about antibiotics' ineffectiveness against viruses.
A UK government representative highlighted their 10-year health strategy addressing AMR, citing progress in reducing antibiotic use in meat production and developing new treatment incentives whilst maintaining international cooperation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
4 hours ago
- Business Standard
Wockhardt's proprietary antibiotic Zaynich gets mentioned in leading U.K. Medical Journal
For its successful use in a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infection A clinically challenging case involving Wockhardt's novel antibiotic Zaynich was recently published in the July 17, 2025 issue of the Journal of Antimicrobial Chemotherapy - AMR, a leading publication by the British Society for Antimicrobial Chemotherapy. The publication details the successful use of Zaynich, a combination of Zidebactam and Cefepime, in treating a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infectionan infection resistant to all available antibiotics in the United States. This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Notably, this patient was infected with two different pathogens - Pseudomonas and Klebsiella, both resistant to all the recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam. The case report detailed the results of genetic analysis of bacterial DNA and determined that Pseudomonas and Klebsiella harbored 4 distinct resistance mechanisms each leading to pan-drug resistance. Initially, the patient was treated for 10 weeks with cefiderocol and eravacycline (a novel tetracycline antibiotic), but the infection persisted, and the Pseudomonas strain became resistant to cefiderocol. The patient continued to suffer from fever and chills, and imaging tests showed new abscesses in the liver clear signs that the infection was not under control. Given the high risk of transplant failure due to these MDR infections, a multidisciplinary team, including microbiologists, infectious disease experts, oncologists, and transplant surgeons, sought emergency access to Zaynich. The antibiotic was administered for 14 days around the time of the liver transplant. The results were remarkable - within 11 days, the patient improved clinically and transferred from ICU to regular floor, and follow-up imaging showed no signs of active infection. Importantly, the patient remained infection-free even after six weeks of completing treatment with Zaynich, making liver transplant successful and allowing doctors to safely resume chemotherapy for the underlying cancer. The authors highlighted the role of Zaynich as a potential treatment option for extensively drug resistant infections with extremely limited/no treatment options. Zaynich is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial, which will support its marketing authorization across international markets. Prior to this, multiple Phase I clinical pharmacology studies involving the Zidebactam/Cefepime combination were successfully conducted in the United States. Zaynich has also completed a multi-indication clinical study in India, specifically targeting carbapenem-resistant infections. To date, more than 50 patients in India and the U.S. suffering from highly resistant infections have been treated with Zaynich under compassionate use programs.
Economic Times
14 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
14 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
